Clinical Trials Directory

Trials / Conditions / Hurler-Scheie Syndrome

Hurler-Scheie Syndrome

11 registered clinical trials studyying Hurler-Scheie Syndrome.

StatusTrialSponsorPhase
SuspendedRGX-111 Gene Therapy in Patients With MPS I
NCT03580083
REGENXBIO Inc.Phase 1 / Phase 2
TerminatedPhase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
NCT01372228
Talaris Therapeutics Inc.Phase 1 / Phase 2
TerminatedA Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysacch
NCT00418821
Genzyme, a Sanofi CompanyPhase 4
CompletedA Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
NCT00852358
Patricia I. Dickson, M.D.N/A
TerminatedExtension Study of Intrathecal Enzyme Replacement Therapy for MPS I
NCT00786968
Patricia I. Dickson, M.D.Phase 1
CompletedStudy of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease
NCT00258011
Genzyme, a Sanofi CompanyPhase 3
CompletedA Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease
NCT00144781
Genzyme, a Sanofi CompanyPhase 4
CompletedA Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosa
NCT00144768
Genzyme, a Sanofi CompanyPhase 4
CompletedA Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Y
NCT00146757
Genzyme, a Sanofi CompanyPhase 2
CompletedPhase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS
NCT00146770
Genzyme, a Sanofi CompanyPhase 3
CompletedClinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I
NCT00912925
Genzyme, a Sanofi CompanyPhase 3